Terpineol enhances antibiotic effectiveness and reduces resistance in clinically relevant bacteria

<h2>Abstract</h2><h3>Background and aim</h3> The synergistic interaction between natural compounds and existing antibiotics (ABXs) offers a promising strategy to enhance ABX efficacy while mitigating resistance. This study evaluated the potential of terpineol (TER), a monocyclic monoterpene of plant origin with antimicrobial properties, as an enhancer of antibiotic activity against 14 clinically and veterinary relevant bacterial strains, including ESKAPE pathogens identified by WHO as urgent targets. <h3>Experimental procedure</h3> The antimicrobial activity of TER and its synergistic effects with 13 commonly used antibiotics were assessed using the checkerboard microdilution method and isobologram representation, with growth kinetics and time-kill curves generated over 24 h. <h3>Key results</h3> TER showed antimicrobial activity against 14 tested bacteria. The lowest MIC was 0.25 mg/mL for <i>Acinetobacter baumannii</i> (WHO priority 1). TER was effective (MIC = 0.5 mg/mL) against various Gram-negative and positive bacteria, exhibiting bactericidal activity in all cases. TER formed additive and synergistic relationships with 11 antibiotics. Six combinations demonstrated synergy (FICi≤0.5), 24 showed additivity (0.5<FICi≤1), and 13 exhibited indifference (1<FICi<4), with no antagonism (FICi≥4). The six TER/ABX synergies resulted in 100 % inhibition of bacterial growth, reducing MICs by up to 87.5 %. For the first time, this study demonstrated that TER minimally generates microbial resistance compared to commercial antibiotics. Additionally, TER acted as an Antimicrobial Resistance Modifying Agent, reducing resistance to four ABXs (gentamycin, florfenicol, chloramphenicol, tetracycline) in both Gram-positive and negative bacteria. <h3>Conclusions and implications</h3> Given its safety profile endorsed by EPA and FDA, TER emerges as a promising candidate for natural antibiotic enhancement, preventing the development of resistance.

Authors

Publication Details

Journal
Heliyon
Published
2025-10-01
DOI
https://doi.org/10.1016/j.heliyon.2025.e43932
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Terpineol enhances antibiotic effectiveness and reduces resistance in clinically relevant bacteria

María Rosa Pino-Otín, Diego Ballestero, Natalia Ferrando, Elisa Langa et al.
Heliyon
Antibiotics Pharmacokinetics and Efficacy
article

Terpineol enhances antibiotic effectiveness and reduces resistance in clinically relevant bacteria

María Rosa Pino-Otín, Diego Ballestero, Natalia Ferrando, Elisa Langa, Cristina Gan, A. Valenzuela
article en

Abstract

<h2>Abstract</h2><h3>Background and aim</h3> The synergistic interaction between natural compounds and existing antibiotics (ABXs) offers a promising strategy to enhance ABX efficacy while mitigating resistance. This study evaluated the potential of terpineol (TER), a monocyclic monoterpene of plant origin with antimicrobial properties, as an enhancer of antibiotic activity against 14 clinically and veterinary relevant bacterial strains, including ESKAPE pathogens identified by WHO as urgent targets. <h3>Experimental procedure</h3> The antimicrobial activity of TER and its synergistic effects with 13 commonly used antibiotics were assessed using the checkerboard microdilution method and isobologram representation, with growth kinetics and time-kill curves generated over 24 h. <h3>Key results</h3> TER showed antimicrobial activity against 14 tested bacteria. The lowest MIC was 0.25 mg/mL for <i>Acinetobacter baumannii</i> (WHO priority 1). TER was effective (MIC = 0.5 mg/mL) against various Gram-negative and positive bacteria, exhibiting bactericidal activity in all cases. TER formed additive and synergistic relationships with 11 antibiotics. Six combinations demonstrated synergy (FICi≤0.5), 24 showed additivity (0.5<FICi≤1), and 13 exhibited indifference (1<FICi<4), with no antagonism (FICi≥4). The six TER/ABX synergies resulted in 100 % inhibition of bacterial growth, reducing MICs by up to 87.5 %. For the first time, this study demonstrated that TER minimally generates microbial resistance compared to commercial antibiotics. Additionally, TER acted as an Antimicrobial Resistance Modifying Agent, reducing resistance to four ABXs (gentamycin, florfenicol, chloramphenicol, tetracycline) in both Gram-positive and negative bacteria. <h3>Conclusions and implications</h3> Given its safety profile endorsed by EPA and FDA, TER emerges as a promising candidate for natural antibiotic enhancement, preventing the development of resistance.

HeliyonVol. 11(15)
Openalex Percentile: Top 69%
Antibiotics Pharmacokinetics and Efficacy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.